文献速递眼底病与葡萄膜炎

地图样萎缩患者接受兰帕利珠单抗注射后的眼压结局

Intraocular Pressure Outcomes After Lampalizumab Injections in Patients With Geographic Atrophy.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

该研究为两项临床试验的事后分析,纳入1851例50岁及以上双侧地图样萎缩患者,比较每4周或每6周玻璃体内注射0.1 mL兰帕利珠单抗或假手术48周的眼压变化。结果显示,两个4周频率组平均注射前眼压至48周无变化,青光眼和高眼压不良事件在兰帕利珠单抗组为1.8%、假手术组为1.6%。作者认为1年内眼压升高罕见,支持0.1 mL注射体积持续1年的眼压升高风险较低。

要点

  • 每4周或每6周玻璃体内注射0.1 mL兰帕利珠单抗至48周,平均注射前眼压无变化。
  • 青光眼和高眼压不良事件报告率:兰帕利珠单抗组1.8%,假手术组1.6%。
  • 作者认为这些发现支持以类似临床试验方式注射0.1 mL体积1年的持续性眼压升高风险较低。

核心结论

  • 作者认为,1年内眼压升高罕见,且治疗组并不比假手术组更常见。
  • 作者认为这些发现支持以类似临床试验方式注射0.1 mL体积1年的持续性眼压升高风险较低。
  • 作者认为这些结果可能对未来考虑该注射体积的治疗试验设计有价值,尤其因为更多新近获批药物使用0.07至0.1 mL的体积。

研究设计与样本

  • 本研究为两项临床试验的事后分析,旨在探讨玻璃体内兰帕利珠单抗对继发于年龄相关性黄斑变性的地图样萎缩的眼压安全性。
  • 两项试验于2014年至2018年间开展,招募50岁及以上、患有双侧地图样萎缩的参与者;该事后分析于2018年至2022年间进行。
  • 干预为玻璃体内注射兰帕利珠单抗0.1 mL每4周、兰帕利珠单抗0.1 mL每6周,或假手术每4周或每6周,持续48周。
  • 共纳入1851例参与者。
  • 主要结局指标为4周频率研究组的眼压变化以及所有组至第48周的眼部不良事件;本分析的假设在数据收集后形成。

主要发现

  • 在共1851例参与者中,两个组至48周的平均注射前眼压值均无变化。
  • 青光眼和高眼压不良事件在兰帕利珠单抗治疗参与者中报告率为1.8%,在假手术组参与者中为1.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本分析的假设在数据收集后形成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intraocular pressure (IOP) elevations of clinical relevance have been observed after the commonly used 0.05-mL volume for intravitreous injections. However, more recently approved intravitreous agents involve volumes from 0.07 to 0.1 mL. It is not well established whether repeated 0.1-mL intravitreous injections may result in IOP-related complications. OBJECTIVE: To investigate the effect of 1 year of repeated 0.1-mL intravitreous injections on IOP outcomes. DESIGN, SETTING, AND PARTICIPANTS: This study was a post hoc analysis of 2 clinical trials investigating the IOP safety of intravitreous lampalizumab on geographic atrophy secondary to age-related macular degeneration. Both trials were conducted between 2014 and 2018 and recruited participants who were 50 years or older and had bilateral geographic atrophy. This post hoc analysis was performed between 2018 and 2022. INTERVENTIONS: Intravitreous lampalizumab, 0.1 mL, every 4 weeks; lampalizumab, 0.1 mL, every 6 weeks; or sham procedure every 4 weeks or 6 weeks for 48 weeks. MAIN OUTCOMES AND MEASURES: IOP changes in the 4-week-frequency study arms and ocular adverse events to week 48 in all arms. The hypothesis for this analysis was formulated after data collection. RESULTS: Among a total of 1851 participants, there was no change in mean pre-injection IOP values through 48 weeks in either arm. The adverse events glaucoma and ocular hypertension were reported for 1.8% of participants treated with lampalizumab and 1.6% of those in the sham arm. CONCLUSIONS AND RELEVANCE: Over 1 year, IOP increases were rare and did not affect treated participants more frequently than sham arm participants. These findings support the low risk of persistent IOP increases, on average, of intravitreous 0.1-mL injection volumes administered for 1 year in a manner similar to that performed in these clinical trials. These results may be valuable in the design of future therapeutic trials considering this volume for injections particularly as more recently approved agents use volumes of 0.07 to 0.1 mL. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02247479 and NCT02247531.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Bressler NM, Freund KB, Bakri SJ, et al. Intraocular Pressure Outcomes After Lampalizumab Injections in Patients With Geographic Atrophy. JAMA Ophthalmol. 2024. PMID: 38900484. doi:10.1001/jamaophthalmol.2024.2061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。